Across TCGA pan-cancer cohorts, ANKRD35 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD35 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ANKRD35 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD35 expression acts as an unfavorable survival marker.

BLCA, STAD, and LIHC are the cancer types where ANKRD35 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.196	0.514	.004	33	view →
STAD	OS	Median	II,III,IV	0.001	0.660	<.001	24	view →
LIHC	DFS	Median	All	0.054	0.544	<.001	18	view →
COAD	OS	Median	All	0.291	0.699	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANKRD35 tumor-vs-normal RNA expression · all ANKRD35 data types